CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 1 TO NON-EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTNon-Exclusive License and Development Agreement • March 16th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment to Non-Exclusive License And Development Agreement (“Amendment No. 1”), effective as of April 12, 2021 (“Amendment No. 1 Effective Date”), is entered into by and between FUJIFILM CELLULAR DYNAMICS, INC., having a place of business at 525 Science Drive, Madison, WI 53711 (“FCDI”), and SANA BIOTECHNOLOGY, INC., having a place of business at 188 East Blaine Street, Suite 400, Seattle, WA 98102 (“Licensee”).
FIFTH AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 16th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Fifth Amendment (this “Fifth Amendment”), is effective as of February 9, 2023 (the “Fifth Amendment Effective Date”), by and between President an Fellows of Harvard University (“Harvard”), and Sana Biotechnology, Inc., a corporation organized and existing under the laws of the State of Delaware (“Licensee”) (together with Harvard, the “Parties” and each individually a “Party”), and amends that certain License Agreement, dated as of March 19, 2019, as amended by those certain Amendments to the License Agreement dated as of June 10, 2019, December 15, 2020, May 20, 2021, and October 25, 2021 by and between Harvard and Licensee (together, the “Agreement”). Capitalized terms used but not defined herein have the respective meanings assigned to them in the Agreement.
CERTAIN CONFIDENTIAL INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED AMENDMENT NO. 2 TO NON-EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTNon-Exclusive License and Development Agreement • March 16th, 2023 • Sana Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment to Non-Exclusive License And Development Agreement (“Amendment No. 2”), effective as of October 26, 2021 (“Amendment No. 2 Effective Date”), is entered into by and between FUJIFILM CELLULAR DYNAMICS, INC., having a place of business at 525 Science Drive, Madison, WI 53711 (“FCDI”), and SANA BIOTECHNOLOGY, INC., having a place of business at 188 East Blaine Street, Suite 400, Seattle, WA 98102 (“Licensee”).
